Trials / Completed
CompletedNCT07191639
Description of the Impact of Symptoms on Quality of Life in HHT Disease: DISQUO
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 185 (actual)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In 2017, the ELECT-RO study led, firstly, to the creation of a tool to measure quality of life (QoL) specific to HHT (hereditary haemorrhagic telangiectasia disease), QoL-HHT, based on patients' experiences, their representations and their difficulties. Secondly, the ELECT-RO study demonstrated the validity of the measurement scale, meaning that QoL-HHT does indeed measure patients' QoL and is therefore a reference tool. QoL-HHT gives investigators a good understanding of the different aspects of patients' QoL (physical limitations, concerns about bleeding, concerns about the evolution of the disease, social relationships, relationships with healthcare professionals and the experience of the disease), whether they are affected or not, at an individual level. Today, investigators believe it is important to take a more global (population-based) view of the aspects of quality of life affected by HHT. While studies have shown the importance of the role of epistaxis (frequency, duration, intensity, experience) in QoL, what about other symptoms and clinical signs? The DISQUO study, which the researchers plan to start today, is a follow-up to ELECT-RO. It should enable the researchers to gain a better understanding of the QoL of people with HHT and the impact of each symptom of HHT on patients' QoL. The DISQUO study will therefore allow the investigators to gain a better understanding of the impact of HHT symptoms on the different areas of patients' QoL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | completion of the QOL-HHT questionnaire | filling in the QOL-HHT questionnaire when they come for consultation |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2024-12-01
- Completion
- 2025-05-01
- First posted
- 2025-09-25
- Last updated
- 2025-09-25
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT07191639. Inclusion in this directory is not an endorsement.